Dyslipidemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Dyslipidemia Market Outlook
Thelansis’s “Dyslipidemia Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Dyslipidemia treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
Dyslipidemia
Overview
Dyslipidemia
is the imbalance of lipids such as cholesterol, triglycerides, low-density
lipoprotein cholesterol (LDL-C), and high-density lipoprotein (HDL). According
to the Frederickson phenotype, dyslipidemia is classified into five categories.
Phenotype I is a chylomicron abnormality that results in triglycerides higher
than the 99 percentiles. Phenotype IIa is characterised primarily by LDL
cholesterol abnormalities, with total cholesterol concentrations greater than
the 90th percentile and possible apolipoprotein B more significant than the 90
percentile. The phenotype IIb consists of abnormality in LDL and very
low-density lipoprotein (VLDL) cholesterol. The most critical complication of
dyslipidemia is cardiovascular disease. This can lead to sudden cardiac death,
acute myocardial infarction, or stroke. Multiple studies have shown that
statins and appropriate dyslipidemia treatment reduce the risk of all-cause
mortality, cardiovascular events, and cardiovascular mortality significantly.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment